<DOC>
	<DOCNO>NCT00229203</DOCNO>
	<brief_summary>This phase II study determine efficacy follow treatment Aplidin® 5 mg/m2 , give 3 hour intravenous infusion every 2 week , patient relapse refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>A Study Aplidin ( Plitidepsin ) 3 h iv Subjects With Relapsing Refractory Multiple Myeloma</brief_title>
	<detailed_description>This phase II study determine efficacy follow treatment Aplidin® 5 mg/m2 , give 3 h iv infusion every 2 week , patient relapse refractory multiple myeloma ( MM ) obtain follow : - Additional pharmacokinetic information Aplidin® give 3-hour IV infusion every 2 week patient MM . - To obtain additional genomic pharmacodynamics information MM Aplidin . - To assess safety tolerability Aplidin® give 3-hour IV infusion every 2 week patient MM alone combination dexamethasone give orally 20 mg daily 4 day - To determine response rate second cohort patient follow treatment Aplidin® , give 3 hour infusion every 2 week , plus dexamethasone give orally 20 mg daily 4 day , start day Aplidin® administration , second treatment stage patient suboptimal response Aplidin® single agent ( progressive disease three cycle stable disease four cycle ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<criteria>Inclusion criterion 1 . Written inform consent obtain patient start studyspecific procedure . If patient unable give consent , may obtain patient 's legal representative accordance local law regulation 2 . Age ≥ 18 year 3 . Performance status Eastern Cooperative Oncology Group ( ECOG ) ≤ 2 4 . Life expectancy ≥ 3 month . 5 . Patient previously diagnose MM base standard criterion currently require treatment MM relapse follow response standard chemotherapy highdose chemotherapy , MM refractory ( i.e. , failure achieve least complete response ( CR ) , partial response ( PR ) stable disease ( SD ) ) recent chemotherapy . 6 . Patient measurable disease , define follow : For secretory multiple myeloma , measurable disease define quantifiable serum monoclonal protein value , applicable , urine lightchain excretion ≥ 200 mg/24 hour . For oligo nonsecretory multiple myeloma , measurable disease define presence soft tissue ( bone ) plasmacytoma determine clinical examination applicable radiograph ( i.e . Magnetic resonance imaging ( MRI ) , Computerized Axial Tomography ( CTScan ) ) . 7 . Recovery nonhematological toxicity derive previous treatment . The presence alopecia National Cancer Institute Common Toxicity Criteria ( NCICTC ) grade &lt; 2 sensitive peripheral neuropathy allow . 8 . Patient follow laboratory value within 14 day day 1 , cycle 1 : Platelet count ≥ 50 x109/L , hemoglobin ≥ 8.0 g/dl absolute neutrophil count ( ANC ) ≥ 1.0x109/L ; low value may accept clearly due bone marrow involvement multiple myeloma . Corrected serum calcium &lt; 14mg/dL . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal . Alanine transaminase ( ALT ) : ≤ 2.5 x upper limit normal . Total bilirubin : ≤ 1.5 x upper limit normal . Calculated Creatinine clearance : ≥ 40 mL/minute ( mean Crockoft Gault´s formula ) . 9 . Left ventricular ejection fraction within normal limit . Exclusion criteria 1 . Prior therapy Aplidin® . 2 . Pregnant lactating woman ; men woman reproductive potential use effective contraceptive method ( double barrier method , intrauterine device , oral contraception ) 3 . History another neoplastic disease . The exception : nonmelanoma skin cancer , carcinoma situ uterine cervix , cancer curatively treat evidence disease least 10 year . 4 . Other relevant disease adverse clinical condition : History presence unstable angina , myocardial infarction , valvular heart disease congestive heart failure . Previous mediastinal radiotherapy . Uncontrolled arterial hypertension despite optimal medical therapy . Previous treatment doxorubicin cumulative dos excess 400 mg/m² . Symptomatic arrhythmia arrhythmia require treatment . History significant neurological psychiatric disorder Active infection Patient know human immunodeficiency virus ( HIV ) positive , Hepatitis B surface antigenpositive active hepatitis C infection . Myopathy clinical situation cause significant persistent elevation creatine kinase ( CK ) ( &gt; 2.5 ULN two different determination perform one week apart ) Significant nonneoplastic liver disease ( e.g . cirrhosis , active chronic hepatitis ) Uncontrolled endocrine disease ( e.g . diabetes mellitus , hypothyroidism hyperthyroidism ) ( i.e . require relevant change medication within last month , hospital admission within last 3 month ) 5 . Limitation patient 's ability comply treatment followup protocol . 6 . Treatment investigational product 30 day period inclusion study radiotherapy 4 week inclusion study . Other previous treatment complete 3 week inclusion study , case high dose chemotherapy , 8 week . 7 . Known hypersensitivity Aplidin® , mannitol , cremophor , ethanol dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Aplidin</keyword>
	<keyword>Plitidepsin</keyword>
	<keyword>PharmaMar</keyword>
</DOC>